;

Theodora Harold to be appointed new CEO at Crescendo Biologics

04/04/2019

Crescendo Biologics Ltd (Crescendo), the drug developer of novel, targeted T-cell enhancing therapeutics, today announces that Theodora Harold, the current CFO, will be appointed as CEO. She will be succeeding Peter Pack who will be stepping down from the position of CEO on 1 May 2019.

Theodora joined Crescendo in October 2016 and has worked in close partnership with Peter in the day-to- day running of the Company ever since. She was central to the recent $70 million fund raising and has had responsibility not only for finance and operations but also, more recently, for business development. She has established strong relationships with Crescendo’s development partners.

Before joining the Company, she held both industry and corporate finance roles with private and listed biotech SMEs including PsiOxus Therapeutics Ltd, MISSION Therapeutics Ltd, OrthoMimetics Ltd and Cytomyx Holdings plc. Prior to this, Theodora qualified as a Chartered Accountant with PricewaterhouseCoopers and read Classics at Trinity College, Cambridge.

Peter remains in his executive position until 1 May 2019 to allow for an orderly succession between him and Theodora, and with the Company. He will continue to support Crescendo as a senior advisor.

Kevin Johnson, Non-Executive Chairman of Crescendo Biologics, said: “Theodora has been a driving force for the Company since she joined. Not only has she made a significant difference to the day-to-day running of the Company, but she has been a major contributor to the corporate, business development and operational strategies.

The decision to appoint Theodora to succeed Peter was a straightforward and a unanimous one because of her in-depth knowledge of the business and industry as a whole. She has worked tirelessly to build the business so far and she has exciting ambitions for the Company in the longer term.”

Kevin added: “On behalf of the Board, I would like to thank Peter for his significant contribution to Crescendo over the years, both as an investor advising the Board and as CEO, where he successfully transitioned the Company from a platform company to a developer of multifunctional therapeutics and also steered the $790 million deal with Takeda. In that time, he has built a strong team around him with one of the key elements being Theodora and he has transformed the business. We wish him the best for the future.”

Theodora Harold, incoming CEO, commented: We have made strong progress over the past few years, with the successful Series B fundraising, rapid advancements in the Takeda collaboration and progress of our lead programme CB307 towards the clinic. We are on track to enter Phase I next year and have a number of programmes following behind. I am excited to be working with such an experienced Board and management team to take Crescendo to the next stage of its development.”

Peter Pack said: “I have been extremely fortunate to work at such an extraordinary Company and with the great team at Crescendo. It is now a very different business to the one I joined back in 2015 and I am very proud of what we have achieved together. I believe the time is right to step down but I will keep tight links with the British biotech industry. It is now my pleasure to hand over the stewardship of the Company to Theodora who has been a significant driver of the business since she joined.”

 

 

Contact us

BABRAHAM RESEARCH
CAMPUS

(+44) 1223 496 000
info@babraham.co.uk

Babraham Bioscience Technologies Ltd
Babraham Research Campus
Cambridge
CB22 3AT, United Kingdom

Press Enquiries

Limewash
01223 813 557
info@limewash.co.uk

Subscribe to our mailing list

Please enter your first name
Please enter your surname
Please enter your email address
Submit
; ;